Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
Description:
Faculty: Taofeek K. Owonikoko, MD, PhD
This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinical trial data on B7-H3–directed antibody-drug conjugates in ES-SCLC, including key efficacy and safety outcomes in pretreated populations. Learners will gain practical guidance on identifying appropriate candidates for these therapies based on trial eligibility and real-world considerations. Emphasis is placed on interprofessional management of treatment-related adverse events to elevate patient safety and continuity of care.